Norio Kubo

Dr. Norio Kubo

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Pancreatology
Verified
Journal Article
Closed access
NHNorifumi Harimoto
Norifumi Harimoto
KHKouki Hoshino
Kouki Hoshino
RMRyo Muranushi
Ryo Muranushi
KHKei Hagiwara
Kei Hagiwara
TYTakahiro Yamanaka
Takahiro Yamanaka
KSKen Shirabe
Ken Shirabe

5 December 2019 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
NKNorio Kubo
Norio Kubo
KSKen Shirabe
Ken Shirabe
Isolated bile leakage (IBL) after hepatectomy is intractable, and various treatment methods for it have been reported. This review aimed to clarify the treatment strategy for IBL by summarizing studies on IBL after hepatectomy without extrahepatic bile duct resection. Thirty‐three cases of IBL were reported. The incidence of IBL is very low, accounting for 0.1%–1% of all hepatectomy cases. The risk factors for IBL are unclear; however, several reports mention that biliary anomaly is associated with a high risk of IBL, with preoperative and intraoperative confirmation of biliary tree anatomy being the most important preventive strategy. Treatment methods for IBL include liver resection, bilioenteric anastomosis, endoscopic treatment, bile duct ablation, percutaneous transhepatic portal vein embolization (PTPE), transcatheter arterial embolization, and use of fibrin glue. The therapeutic methods should be chosen depending on remnant liver function, amount of bile leakage, and the liver volume causing the bile leakage. When there is bile leakage from less than one segment, non‐surgical treatment is recommended, whereas when there is bile leakage from one or more segments, surgical treatment can be recommended. Nevertheless, recently, non‐surgical treatment such as PTPE, PTPE with bile duct ablation, and endoscopic methods have been considered as effective treatment approaches.

25 May 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YSYuki Shimoda
Yuki Shimoda
YUYasunari Ubukata
Yasunari Ubukata
THTadashi Handa
Tadashi Handa
Takehiko YokoboriTakehiko Yokobori
Takehiko Yokobori
TWTakayoshi Watanabe
Takayoshi Watanabe
TOTetsunari Oyama
Tetsunari Oyama
Hepatocellular carcinoma (HCC) is one of the major causes of tumor death; thus, the identification of markers related to its diagnosis and prognosis is critical. Previous studies have revealed that epithelial-to-mesenchymal transition (EMT) is involved in tumor invasion and metastasis, and the forkhead box protein C2 (FOXC2) has been shown to promote tumor cell proliferation, invasion, and EMT. In the present study, we examined the clinicopathological significance of FOXC2 and EMT-related markers in clinical HCC specimens and identified factors related to the diagnosis and prognosis of HCC. The expression of FOXC2 and EMT-related markers was evaluated by immunohistochemistry in 84 cases of hepatocellular carcinoma. A high expression of FOXC2 was observed in 26 of 84 cases, and expression was significantly correlated with background liver cirrhosis, poor tumor differentiation, high serum AFP, and elevated cell proliferation markers. In addition, this high expression was related to the induction of the Cadherin switch and vimentin expression and was an independent predictor for poor prognosis. The high expression of FOXC2 in HCC is correlated with tumor malignancy and poor prognosis, suggesting that FOXC2 may be an important prognostic factor for HCC.

15 March 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
TYTakahiro Yamanaka
Takahiro Yamanaka
NHNorifumi Harimoto
Norifumi Harimoto
Takehiko YokoboriTakehiko Yokobori
Takehiko Yokobori
RMRyo Muranushi
Ryo Muranushi
KHKouki Hoshino
Kouki Hoshino
KSKen Shirabe
Ken Shirabe
Treatment of hepatocellular carcinoma (HCC) is currently challenging. Cancer-associated fibroblasts (CAFs) promote the malignancy of HCC cells via production of cytokines. Conophylline (CnP), a vinca alkaloid obtained from Ervatamia microphylla leaves, has been reported to suppress activation of hepatic stellate cells and liver fibrosis in rats. We examined the efficacy of CnP in suppressing tumor growth in HCC. Specifically, we investigated whether CnP could inhibit CAFs, which were derived from HCC tissues in vitro and in vivo. Same as previous reports, CAFs promoted proliferative and invasive ability of HCC cells. CnP suppressed α-smooth muscle actin expression of CAFs, and inhibited their cancer-promoting effects. CnP significantly suppressed CAFs producting cytokines such as IL6, IL8, C-C motif chemokine ligand 2, angiogenin, and osteopontin (OPN). Combined therapy with sorafenib and CnP against HCC cells and CAFs in vivo showed to inhibit tumor growth the most compared with controls and single treatment with CnP or sorafenib. Transcriptome analysis revealed that GPR68 in CAFs was strongly suppressed by CnP. The cancer-promoting effects of cytokines were eliminated by knockdown of GPR68 in CAFs. CnP inhibited the HCC-promoting effects of CAFs by suppressing several HCC-promoting cytokines secreted by CAFs expressing GPR68. Combination therapy with CnP and existing anticancer agents may be a promising strategy for treating refractory HCC associated with activated CAFs.

15 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
NHNorifumi Harimoto
Norifumi Harimoto
KAKenichiro Araki
Kenichiro Araki
NKNorio Kubo
Norio Kubo
AWAkira Watanabe
Akira Watanabe
KSKen Shirabe
Ken Shirabe
The efficacy and prognosis of adjuvant chemotherapy for resected pancreatic cancer remain unclear. We investigated the utility and risk factors of S-1 adjuvant chemotherapy in patients with pancreatic cancer undergoing pancreatectomy. This study comprised 80 patients, including 58 patients who received S-1 adjuvant chemotherapy. Skeletal muscle loss was defined using cutoff values of skeletal muscle mass index. In total, 16 (20%) octogenarian patients underwent pancreatectomy. Skeletal muscle loss was present in 56 (70%) patients. The entire course of S-1 adjuvant chemotherapy for 6 months was completed in 33 patients (41%). S-1 adjuvant chemotherapy <6 months was an independent prognostic indicator of poor overall survival. Patients who completed S-1 adjuvant chemotherapy exhibited significantly longer overall and relapse-free survival rates than those did not complete the chemotherapy (p < 0.0001 and p = 0.0003, respectively). Being an octogenarian and skeletal muscle loss were independent variables associated with the discontinuation of S-1 adjuvant chemotherapy. Finally, the S-1 adjuvant chemotherapy rates were 6.3% (1/16) and 28.6% (16/56) in octogenarian patients and those with skeletal muscle loss, respectively. S-1 adjuvant chemotherapy completion was associated with improved prognosis in patients with pancreatic cancer. Skeletal muscle loss and octogenarian status predicted the failure of S-1 adjuvant chemotherapy completion.

1 April 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
KAKenichiro Araki
Kenichiro Araki
FSFumiyoshi Saito
Fumiyoshi Saito
NKNorio Kubo
Norio Kubo
AWAkira Watanabe
Akira Watanabe
HKHiroyuki Kuwano
Hiroyuki Kuwano